Zepbound: First Approved Treatment for Sleep Apnea in Obese Adults
Zepbound is now the first FDA-approved medication for treating moderate-to-severe obstructive sleep apnea in adults with obesity, offering new hope for sufferers.
Topic
obesity
A collection of 4 issues
Zepbound Promises 18% Weight Loss in Clinical Trials
Discover how Zepbound helps patients achieve 18% body weight loss in clinical trials, offering hope for obesity management. Learn more about this breakthrough.
Obesity Drugs: The Rising Star in Pharma
Explore the booming trend of obesity drugs in the pharmaceutical sector, offering high stakes and immense market potential. Discover key insights now.
Novo Nordisk's Obesity Shot Trial Misses Mark
Novo Nordisk A/S faces a setback with disappointing trial results for its obesity shot, marking a turbulent year for the pharmaceutical giant.